Preclinical data on ERX-208 and ERX-315 to be presented at AACR 2025

Chicago, IL – April 23, 2025:

Three abstracts with preclinical data on ERX-208 and ERX-315 will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 in San Diego. These abstracts will establish ERX-208 as a powerful breakthrough in ovarian cancer treatment, rigorously assess synergy of ERX-208 with FDA-approved drugs, and validate ERX-315, an Etira drug in Phase 1 trial (NCT06533332), for impact in liver cancer.

“Our preclinical work has validated the targeting of LIPA with ERX-208 and ERX-315 in multiple ovarian and hepatocellular cancer subtypes respectively. We are establishing a clear paradigm for the expanded use of these novel agents either alone or in combination with existing drugs” said Dr. Ratna Vadlamudi, UT Health San Antonio.

Russell Hayward, CEO, Etira added “This research provides additional validation for our clinical-stage programs across multiple cancer types. We are excited about its impact on our ongoing clinical trials with ERX-315.”

PRESENTATIONS

  • Oral presentation at AACR Mini-Symposium:
    • Title: “Optimization of the LIPA Targeting Agent for the Treatment of Ovarian Cancer”
    • Session:CH01.01 Innovative Approaches in Drug Discovery: Novel Leads, Degraders and AI-driven solutions
    • Presenter: Ratna Vadlamudi, UT Health San Antonio
    • Date: April 28, 2025 2:35pm- 2:50pm
    • Conclusions: ERX-208 targets LIPA and potently causes catastrophic endoplasmic reticulum stress in multiple ovarian cancer subtypes.
    • Implications: ERX-208 is a viable candidate for clinical translation in ovarian cancer
  • Poster presentation
    • Title: “Targeting ER stress for treating hepatocellular carcinoma (HCC)”
    • Session:ET06.01 Cell Death Pathways and Treatment
    • Presenter: Adriana Baker, UT Health San Antonio
    • Date: April 28, 2025 9:00am- 12:00pm
    • Conclusions: ERX-315 targets LIPA and potently causes catastrophic endoplasmic reticulum stress in multiple subtypes of hepatocellular cancer.
    • Implications: Ongoing ERX-315 clinical trials should include patients with advanced liver cancer
  • Poster presentation Undergraduate symposium
    • Title: “Combining LIPA inhibitor ERX-208 with DNA-damaging agents as a novel strategy to enhance ovarian cancer treatment
    • Presenter: Durga Meenakshi Panneerdoss, UT Health San Antonio
    • Date: April 26, 2025
    • Conclusions: In an unbiased evaluation of combination of ERX-208 with 147 FDA-approved chemotherapeutic agents, ERX-208 was noted to be synergistic with DNA-damaging agents like cisplatin.
    • Implications: Combination of ERX-208 with DNA-damaging agents such as cisplatin are more effective in ovarian cancers than ERX-208 or cisplatin alone.

 

Etira’s ERX-315-101 Phase 1 study is an open-label dose escalation and cohort expansion trial to evaluate the safety and tolerability of ERX-315 in patients whose cancers no longer respond to approved systemic therapies.

Click on Abstract titles below to read more:

Targeting ER stress for treating hepatocellular carcinoma (HCC)[78]

Optimization of the LIPA targeting agent for the treatment of ovarian cancer[18]

/by